Development and characterization of a first-in-class adjustable-dose gene therapy system

CONCLUSION: We report the development of a novel, low-cost therapeutic platform, designed to enable the replacement of subcutaneously administered protein treatments with a single-injection, adjustable-dose gene therapy.PMID:38663689 | DOI:10.1016/j.gene.2024.148500

Source: Gene - April 25, 2024 Category: Genetics & Stem Cells Authors: Alex Goraltchouk Jared Lourie Judith M Hollander H Grace Rosen Atsutaro A Fujishiro Francesco Luppino Kai Zou Alexey Seregin Source Type: research